Prosecution Insights
Last updated: November 05, 2026
Application No. 18/661,641

PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING ULCER OR FISTULA IN INTESTINAL TRACT

Non-Final OA §103§112§DOUBLEPATENT
Filed
May 12, 2024
Priority
Oct 05, 2018 — JP 2018-189712 +3 more
Examiner
BEANE, RANDALL L
Art Unit
1654
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
3-D Matrix Ltd.
OA Round
1 (Non-Final)
33%
Grant Probability
At Risk
1-2
OA Rounds
9m
Est. Remaining
69%
With Interview

Examiner Intelligence

Grants only 33% of cases
33%
Career Allowance Rate
151 granted / 459 resolved
-27.1% vs TC avg
Strong +36% interview lift
Without
With
+36.3%
Interview Lift
resolved cases with interview
Typical timeline
3y 3m
Avg Prosecution
58 currently pending
Career history
524
Total Applications
across all art units

Statute-Specific Performance

§101
4.4%
-35.6% vs TC avg
§103
31.5%
-8.5% vs TC avg
§102
14.9%
-25.1% vs TC avg
§112
32.9%
-7.1% vs TC avg
Black line = Tech Center average estimate • Based on career data from 459 resolved cases

Office Action

§103 §112 §DOUBLEPATENT
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Status Claims 31 and 33-38 are pending. Claims 31 and 33 were amended, and claim 32 was canceled in the Reply filed 9/29/2026. Claims 35-38 are withdrawn as directed to a non-elected species. Claims 31 and 33-34 are presently considered. Election/Restrictions Applicant’s election of Example 1 in the reply filed on 9/29/2026 is acknowledged. Because applicants did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (MPEP § 818.01(a)). The originally elected species is understood as follows: The response identifies that the election is to a narrow subgenus of patentably indistinct species (see also Reply filed 9/29/2026 at 6 at § VI “Patentably indistinct species”). The patentably indistinct species are understood to be variants of Example 1 of the specification (see, e.g., Spec. filed 5/12/2024 at ¶¶[0058]-[0066], Figs. 2-10): The patient population is understood to be a TNBS-induced colonic ulcer rat model (see, e.g, Spec. filed 5/12/2024 at ¶¶[0058]-[0066], Figs. 2-10), which is identified as representative of “ulcerative colitis” in humans (see also Reply filed 9/29/2026 at 5-6 at §§ II and VI). The administered composition and dosage is understood to require that “PuraMatrix” (i.e., instant SEQ ID NO: 1, (RADA)4, a.k.a. RADA161), which is administered to subjects at 2.5% weight in water (see, e.g, Spec. filed 5/12/2024 at ¶¶[0058]-[0066], Figs. 2-10; see also Reply filed 9/29/2026 at 6 at § III). The route of administration is understood to be local administration using an endoscope (see, e.g, Spec. filed 5/12/2024 at ¶[0059]; see also Reply filed 9/29/2026 at 6 at § IV). The dosage frequency in the subgenus of patentably indistinct species is understood to range from multiple administrations (e.g., day 2, 4, and 7) to a single “on time administration” (see, e.g, Reply filed 9/29/2026 at 6 at § V) Applicant identifies that the originally elected species is representative of treatment of “refractory ulcers in the intestinal tract in inflammatory bowel disease” (see, e.g, Reply filed 9/29/2026 at 6 at §§ V-VI). The originally elected subgenus of patentably indistinct species do not read upon instant claims 35-38, at least because such species do not require additional drugs. Following extensive search and examination, the originally elected species has been deemed anticipated and/or obvious in view of the prior art as applied below. Per MPEP § 803.02(III)(A), Following election, the Markush claim will be examined fully with respect to the elected species and further to the extent necessary to determine patentability. Note that where a claim reads on multiple species, only one species needs to be taught or suggested by the prior art in order for the claim to be anticipated or rendered obvious... If the Markush claim is not allowable, the provisional election will be given effect and examination will be limited to the Markush claim and claims to the elected species, with claims drawn to species patentably distinct from the elected species held withdrawn from further consideration. Accordingly, claims 31 and 33-34 are rejected in view of the originally elected species and claims that do not read upon the originally elected species are withdrawn. Claims 35-38 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected species, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on 9/29/2026. Claims 31 and 33-34 are presently considered. Priority The priority claim to JP2018-189712 (filed 10/05/2018) is acknowledged. A certified translation was submitted in US Application No. 17/250,969 on May 11, 2024. Information Disclosure Statement The IDS filed 5/29/2024; 5/29/2025; 2/06/2025; and 9/01/2026 are acknowledged and presently considered. Applicant should note that one or more documents disclosed on the IDS form submitted on 2/06/2025 were not considered since they did not conform to 37 CFR 1.98(b) by providing a proper date, as 37 CFR 1.98(b) requires that each publication must be identified by publisher, author (if any), title, relevant pages of the publication, and date and place of publication. The date of publication supplied must include at least the month and year of publication, except that the year of publication (without the month) will be accepted if the applicant points out in the information disclosure statement that the year of publication is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the particular month of publication is not in issue. See MPEP 609.04(a). Here, the earliest priority claim is to JP2018-189712, filed 10/05/2018); therefore, all documents published in 2017 or later must be accompanied by both month and date of publication. References that were not considered have been indicated by strike-though on the attached IDS forms. Although not considered, these documents have been placed in the application file, but the information referred to therein has not been considered as to the merits. Applicant is advised that the date of any re-submission of any item of information contained in this information disclosure statement or the submission of any missing element(s) will be the date of submission for purposes of determining compliance with the requirements based on the time of filing the statement, including all certification requirements for statements under 37 CFR 1.97(e). See MPEP § 609.05(a). Claim Interpretation For purposes of examination, the claim scope has been interpreted as set forth below per the guidance set forth at MPEP § 2111. If Applicant disputes any interpretation, Applicant is invited to unambiguously identify any alleged misinterpretations or specialized definitions in the subsequent response to the instant action. Applicant is advised that a specialized definition should be properly supported and specifically identified (see, e.g., MPEP § 2111.01(IV), describing how Applicant may act as their own lexicographer). Claim 1 is representative of the pending claim scope and presently recites: 31. (Currently Amended) A method of treating or preventing a refractory ulcer in the intestinal tract of a human subject, the method comprising: a step of applying a pharmaceutical composition containing a therapeutically effective amount of a self-assembling peptide to an ulcer site of the subject having a refractory ulcer in the intestinal tract, wherein the self-assembling peptide is a peptide consisting of RADARADARADARADA (SEQ ID NO:1), and wherein the ulcer in the intestinal tract is caused by ulcerative colitis, Crohn's disease or Behcet's disease, thereby treating the subject's refractory ulcer . Accordingly, the claimed invention is a method of treating. Additional claim interpretations are discussed below. “Comprising” is an open-ended transitional term (see, e.g., MPEP § 2111.03(I)), wherein additional steps or components are not excluded. However, “‘[c]omprising’ is a term of art used in claim language which means that the named elements are essential” (see, e.g., id.; see also Genentech, Inc. v. Chiron Corp., 112 F.3d 495, 501, 42 USPQ2d 1608, 1613 (Fed. Cir. 1997)). “Consisting of” excludes any elements, step, or ingredient not specified (see, e.g., MPEP § 2111.03(II)). When the phrase "consists of" appears in a clause of the body of a claim, rather than immediately following the preamble, the "consisting of" phrase limits only the element set forth in that clause; other elements are not excluded from the claim as a whole (see, e.g., MPEP § 2111.03(II)). The term “therapeutically effective amount” (i.e., dose and frequency) is not specified in the claims nor in the originally filed disclosure, but instead identified as “appropriately determined by a person having ordinary skill in the art” (see, e.g., Spec. filed 4/02/2021 at ¶[0033]). Accordingly, in the absence of guidance and clarification, any dose and dosage frequency utilized in the prior art capable of eliciting any “therapeutic” effect is reasonably inferred to necessarily and inherently satisfy the claim requirement and is deemed a “therapeutically effective amount” in the absence of evidence to the contrary. “Treating or preventing” are not defined in the originally filed disclosure. Accordingly, such terms are given their broadest reasonable interpretation, wherein “treating” includes prophylactic treatment. “Ulcer” is undefined on record, and is therefore given the broadest, reasonable interpretation consistent with the plain meaning of the term. Specifically, an “ulcer” is an open sore, break, or lesion on the skin or an internal mucous membrane caused by tissue loss, inflammation, or infection, wherein there is loss or erosion of the top layer of the skin or mucous membrane (the epithelium) that exposes the underlying tissue. “Refractory ulcer” is not defined on record, but is exemplified as an ulcer “exhibiting resistance to, for example, a general conservative treatment (for example, nutrition therapy, drug therapy, or the like) for inflammatory bowel disease” (see, e.g, Spec. filed 5/12/2024 at ¶[0030]), wherein the “refractory ulcers and fistulas [are] caused by inflammatory bowel disease (ulcerative colitis and Crohn’s disease)” (see, e.g, Spec. filed 5/12/2024 at ¶[0029]; see also id. at ¶[0004]). The accepted meaning in the art is narrower, and is understood to refer to “ulcers that do not heal completely after 8 to 12 weeks of standard anti-secretory drug treatment” (see, e.g., Kim2 at title, abs). For purposes of applying prior art, the term is deemed satisfied by treatment for any art-recognized “refractory ulcer” or “refractory” condition characterized by the presence of ulcers. “Ulcerative colitis” is undefined on record, and is therefore given the broadest, reasonable interpretation consistent with the plain meaning of the term. Specifically, “ulcerative colitis” is a disease or condition directly characterized by chronic inflammation and the formation of tiny, open sores (ulcers) in the innermost lining (mucosa) of the large intestine and rectum, wherein there are “continuous lesions” (ulcers) (see, e.g., Lee et al. at title, abs, 370 at col II at 2nd full ¶, 371 at Fig. 13). Therefore, a diagnosis of “ulcerative colitis” is reasonably inferred to mean that ulcers are present, and a diagnosis of “refractory ulcerative colitis” is understood to mean that the ulcers characterizing the condition are “refractory ulcers”. “Crohn’s disease” is undefined on record, and is therefore given the broadest, reasonable interpretation consistent with the plain meaning of the term. Specifically, “Crohn’s disease” is a disease or condition that presents with “discontinuous inflammatory lesions” (ulcers) (see, e.g., Lee et al. at title, abs, 371 at col I-II at bridging ¶, 371 at Fig. 2). Accordingly, a diagnosis of “refractory Crohn’s disease” would be reasonably understood to mean that the ulcers present were “refractory ulcers”. “Behçet's disease” is undefined on record, and is therefore given the broadest, reasonable interpretation consistent with the plain meaning of the term. Specifically, “Behçet's disease” is characterized by “A few ulcers with discrete margins” (see, e.g., Lee et al. at title, abs, 372 at col II at 1st full ¶, Fig. 4 on 372). Accordingly, a diagnosis of “refractory Behçet's disease” would be reasonably understood to mean that the ulcers present were “refractory ulcers”. “Intestinal tract” is not explicitly defined in the originally filed disclosure, and therefore the term is given the broadest reasonable interpretation in view of the art consistent with the originally filed disclosure. Specifically, the “intestinal tract” is reasonably understood to include at least the small intestine (e.g., duodenum, jejunum, ileum) the large intestine (e.g., cecum, appendix, ascending colon, right colic flexure, traverse colon, left colic flexure, descending colon, sigmoid colon, rectum, and anal canal), and associated serosa and intestinal wall components. The clause “wherein the ulcer in the intestinal tract is caused by ulcerative colitis, Crohn's disease or Behcet's disease” is understood to limit the applicable patient population to patients having ulcerative colitis, Crohn's disease or Behcet's disease. Additional claim interpretations are discussed below. Claim Objections Claim 31 is objected to because of the following informalities: “Behcet’s disease” should be “Behçet's disease” at claim 31, as the condition is named after Turkish dermatologist Dr. Hulusi Behçet. Appropriate correction is required. Claim Rejections Claim Rejections - 35 USC § 112(b) The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 31 and 33-34 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 31 recites the term “intestinal tract”, which renders the claim scope indefinite in the absence of a clear definition. Although the term “intestinal tract” is commonly utilized as a synonym for “gastrointestinal tract” and “digestive tract” in the art4, such terms are also utilized as separate and distinct terms of art5. This creates ambiguity in the absence of a clear definition because it is prima facie unclear if the term “intestinal tract” as used here includes only the small intestine (e.g., duodenum, jejunum, ileum), the large intestine (e.g., cecum, appendix, ascending colon, right colic flexure, traverse colon, left colic flexure, descending colon, sigmoid colon, rectum, and anal canal), and associated serosa and intestinal wall components thereof; or if the term also encompasses the esophagus, stomach, pharynx, tongue, oral cavity, gallbladder, pancreas, etc. This substantially and materially alters the scope of the pending claims. Accordingly, the pending claim scope is rendered indefinite because it is unclear what infringes or does not infringe upon the invention as claimed. For purposes of applying prior art, the term “intestinal tract” is understood to include at least the small intestine (e.g., duodenum, jejunum, ileum), the large intestine (e.g., cecum, appendix, ascending colon, right colic flexure, traverse colon, left colic flexure, descending colon, sigmoid colon, rectum, and anal canal), and associated serosa and intestinal wall components thereof. Clarification is required. Claim 31 recites the term “refractory ulcer”, which renders the claim scope indefinite. Where applicant acts as his or her own lexicographer to specifically define a term of a claim contrary to its ordinary meaning, the written description must clearly redefine the claim term and set forth the uncommon definition so as to put one reasonably skilled in the art on notice that the applicant intended to so redefine that claim term. Process Control Corp. v. HydReclaim Corp., 190 F.3d 1350, 1357, 52 USPQ2d 1029, 1033 (Fed. Cir. 1999). The term “refractory ulcer” in claim 31 is used by the claim to mean “an ulcer “exhibiting resistance to, for example, a general conservative treatment (for example, nutrition therapy, drug therapy, or the like) for inflammatory bowel disease” (see, e.g, Spec. filed 5/12/2024 at ¶[0030]), while the accepted meaning is “ulcers that do not heal completely after 8 to 12 weeks of standard anti-secretory drug treatment” (see, e.g., Kim6 at title, abs). Accordingly, the term is used on record to imply a substantially broader genus of ulcers, not limited to the definition of the prior art (e.g., specific time frames, specific resistance to standard anti-secretory drug treatment), but the metes and bounds of the term are not redefined on record in a manner permitting an artisan to reasonably identify what types of ulcers are included or excluded by the pending claim scope. This is pertinent because close prior art exists (see, e.g., US 9724448 B2 at col. 21 at lines 30-41, teaching the application of RADA16 to an ESD-induced ulcer, wherein the primary end-point was a reduction of post-ESD bleeding, and the secondary endpoint included the transitional rate to healing and scarring stages of gastric ESD-induced ulcers; see additional prior art, cited below). Accordingly, the term “refractory ulcer” renders the claim scope indefinite because the term is not utilized consistently with the art-recognized definition, but the term is not clearly redefined on record in a manner permitting artisans to identify the metes and bounds of the claim scope. The term is indefinite because the specification does not clearly redefine the term. At claim 1, the phrase “preventing a refractory ulcer” does not make sense in context of the active method steps, wherein a composition is administered to “an ulcer site” in a subject “having a refractory ulcer”, and therefore the claim scope is indefinite. Where applicant acts as his or her own lexicographer to specifically define a term of a claim contrary to its ordinary meaning, the written description must clearly redefine the claim term and set forth the uncommon definition so as to put one reasonably skilled in the art on notice that the applicant intended to so redefine that claim term. Process Control Corp. v. HydReclaim Corp., 190 F.3d 1350, 1357, 52 USPQ2d 1029, 1033 (Fed. Cir. 1999). The term “preventing” in claim 31 is used by the claim to mean an intended treatment requiring the existence of an “ulcer site” in a “subject having a refractory ulcer” (see, e.g., instant claim 31), while the accepted meaning of “preventing” is to stop something from occurring (e.g., stopping ulcer formation in a patient at risk of refractory ulcers). Here, as used in the context of amended claim 31, it is prima facie unclear what is actually being “stopped from occurring”, since the active method step requires an “ulcer site” and a patient “having a refractory ulcer” to exist concurrently, which means that refractory ulcer formation is not being prevented or “stopped from occurring”. Clarification is required. For purposes of applying prior art, the preamble has been examined as “a method of treating a refractory ulcer . . .”. Claims 33-34 depend from an indefinite base claim and fail to clarify the indefiniteness of the base claim. Accordingly, claims 33-34 are rejected for reasons applied to the base claim, as discussed above. Accordingly, claims 31 and 33-34 are rejected. Claim Rejections - 35 USC § 112(a), Scope of Enablement The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 31 and 33-34 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, because the specification, while being enabling for treating refractory ulcers, does not reasonably provide enablement for preventing refractory ulcers as presently claimed. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to use the invention commensurate in scope with these claims. The applicable legal standards for enablement are discussed at MPEP § 2164 and the specific legal standards relevant to determinations regarding the scope of enablement are set forth at MPEP § 2164.08. MPEP § 2164 identifies the following relevant factors for determining “undue” experimentation: (A) The breadth of the claims; (B) The nature of the invention; (C) The state of the prior art; (D) The level of one of ordinary skill; (E) The level of predictability in the art; (F) The amount of direction provided by the inventor; (G) The existence of working examples; and (H) The quantity of experimentation needed to make or use the invention based on the content of the disclosure.” The factors which have led the Examiner to conclude that the specification fails to teach how to make and/or use the claimed invention without undue experimentation, are addressed in detail below. The claim scope, reduction to practice, and teachings set forth in the instant disclosure have been discussed in preceding rejections, and those discussions are incorporated into the instant rejection. The breadth of the claims and nature of the invention: Claim 31 is representative of the pending claim scope, and the scope includes the prevention of refractory ulcers caused by Ulcerative colitis, Crohn’s disease, and Behçet's disease. The amount of direction or guidance presented and the existence of working examples: Zero examples showing prevention of refractory ulcers caused by Ulcerative colitis, Crohn’s disease, and/or Behçet's disease was reduced to practice. As presently drafted, “prevention” appears impossible and inconsistent with the recited active method steps. Specifically, it is unclear how or what is reasonably “prevented” since instant claim 31 recites active method steps requiring the pre-existence of “an ulcer site” in a subject “having a refractory ulcer”. Accordingly, it is unclear how something can be “prevented” if the method actually requires that it already exists. Accordingly, as claimed, the full scope is not enabled (see also Rejection under 35 USC 112(b), above, that discussion is incorporated herein). The state of prior art: Even assuming arguendo that the claim scope is interpreted as a prophylactic method (i.e., rather than “an ulcer site”, a “potential or suspected site that may form an ulcer”; i.e., rather than in a subject “having a refractory ulcer”, in a “subject at risk of forming a refractory ulcer”), the claim scope would still not be fully enabled for “preventing”, because such disorders are recognized in the art as not being “preventable” even years after the effective filing date of the instant case (see, e.g., HexaHealth7 at 5 at § “Prevention of Ulcerative Colitis”, explaining that “there isn’t a confirmed method to prevent ulcerative colitis”). Accordingly, zero evidence refractory ulcers caused by Ulcerative colitis, Crohn’s disease, and Behçet's disease can be “prevented” exists in the prior art or in view of the instant record. Relative skill of those in the art, and the predictability or unpredictability of the art: Although the relative skill in the art is high, the general predictability of the art regarding the prevention of poorly understood diseases with unknown mechanisms and pathology is very low. Specifically, an artisan would have a high degree of skepticism regarding claims of preventing a disease or condition widely believed to be unpreventable in the complete absence of any supporting experimental evidence supporting such claims. The quantity of experimentation required to practice the claimed invention based on the teachings of the specification. While methods of treating various conditions using peptides were known in the art at the time of the invention, it was not routine in the art to “prevent” refractory ulcers caused by Ulcerative colitis, Crohn’s disease, and Behçet's disease, as explained above. Therefore, at the time of filing, an artisan would reasonably doubt that such “prevention” was possible to achieve in the absence of credible and substantial guidance. No such credible and substantial guidance has been set forth on record. Accordingly, to practice the full scope of the instant invention, including 100% prevention of such diseases and conditions, an artisan would be unduly burdened to actually identify an “effective” dose for a particular patient population (age, gender, weight, etc.), etc.; however, HexaHealth suggests that such a dosage was still unknown years after the instant Application was publicly disclosed. Conclusion: Therefore, in view of the lack of guidance and working examples, high degree of unpredictability, and failure to address the concerns present in the art, an artisan would be unduly burdened with experimentation in order to practice the full scope of the instantly claimed invention. Accordingly, claims 31 and 33-34 are rejected. Applicant is advised that this rejection could be overcome by amending claim 31 to remove the phrase “or preventing”. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claims 31 and 33-34 are rejected under 35 U.S.C. 103 as being unpatentable over Ungaro et al.8 in view of US 2008/0091233 A1 (Apr. 17, 2008; Ellis-Behnke et al.). Claim interpretation: The applicable claim interpretation has been set forth in a preceding section above, and those interpretations are incorporated into the instant rejection. As explained above, “refractory ulcerative colitis” would be readily understood by artisans to be characterized by “refractory ulcers”. Additional claim interpretations are set forth below. Regarding instant claims 31, 33-34, and the existence of patients having refractory ulcerative colitis characterized by ulcers, in need of treatment of such ulcers, Ungaro discusses Ulcerative colitis (UC) and refractory ulcerative colitis (see, e.g., Ungaro at title, abs, Fig. 2 on 1758, 1760 at col I-II at bridging ¶ referring to ulcerations and referring to “Ulcers in ulcerative colitis…”, 1761 at col II at 1st full ¶ referring to “steroid-refractory ulcerative colitis”, 1763 at col I at 2nd full ¶ referring to ulcerative colitis that is “refractory to standard medications”, 1763 at col II at 1st full ¶ identifying that surgery may be required in refractory ulcerative colitis). Accordingly, refractory ulcerative colitis, characterized by ulcers, was known in the prior art (see id.). Ungaro reasonably informs artisans that there is a need for non-surgical treatment of refractory ulcerative colitis and associated ulcers and also that research for improved treatments and surgical options are ongoing (see, e.g., Ungaro at abs, Fig. 4 at 1762, Fig. 5 at 1763, 1765 at § “Future directions and controversies” at col I-II). The primary reference differs from the instant claim scope and elected species as follows: Ungaro does not direct artisans to treat ulcers in refractory ulcerative colitis (i.e., refractory ulcers) by locally administering via endoscope a peptide consisting of (RADA)4 (i.e., instant SEQ ID NO: 1) to the “ulcer site” of a subject. However, in view of Ungaro, an artisan attempting to treat ulcers in refractory ulcerative colitis would begin by reviewing the prior art for known methods of treating all types of gastrointestinal ulcers. Regarding instant claim 31, 33, and the step of administering via endoscope a peptide consisting of (RADA)4 to an ulcer within the gastrointestinal tract of a patient, US’233 identifies methods for treating any type of ulcer (see, e.g., US’233 at abs, ¶¶[0019], [0144], [0163]-[0164], [0173]), including ulcers located in the gastrointestinal tract in the esophagus, stomach, small intestine, large intestine, or rectum (see, e.g., US’233 at ¶[0173]), wherein a composition comprising (RADA)4 is administered (see, e.g., US’233 at ¶[0186], identifying that “RADA 16-1” is RADARADARADARADA; see also id. at ¶¶[0186], [0193], [0198], [0202], [0204], [0206], noting that SEQ ID NO: 1 is the only peptide tested in all examples), wherein administration is performed locally via an endoscope (see, e.g., US’233 at ¶[0144], [0183], [0173], explaining “endoscopic therapeutic approaches” for gastrointestinal ulcers wherein administration is made “at, or in the vicinity of, an ulcer”). Regarding instant claim 31, 34, and a composition comprising a peptide consisting of (RADA)4 at 0.1% to 10.0% by weight, US’233 directs artisans to utilize (RADA)4, because it is the only compound utilized in all exemplified embodiments (see, e.g., US’233 at ¶¶[0186], [0193], [0198], [0202], [0204], [0206]). Furthermore, US’233 identifies that such compositions may be utilized at “useful concentration” ranges of 0.1-10% (see, e.g., US’233 at ¶[0166]; see also id. at ¶[0061]), and exemplifies 1% peptide solutions (see id. at ¶¶[0186], [0193], [0198]), 2% peptide solutions (see id. at ¶¶[0202]), and 3-4% peptide solutions (see id. at ¶¶[0190]9; see also MPEP § 2144.05(I), explaining where the claimed ranges "overlap or lie inside ranges disclosed by the prior art" a prima facie case of obviousness exists). Regarding claim 31 and a “therapeutically effective amount”, US’233 identifies that the disclosed compositions would be administered “in an effective amount in order to achieve a clinically significant result” (see, e.g., US’233 at ¶[0079]), wherein the exact amount will depend upon patient parameters, such as the size and depth of the ulcer (see, e.g., US’233 at ¶¶[0140]-[0142]). Regarding claim 31, and frequency of administration, US’233 specifically discusses formulations, and notes that dosing frequency may be reduced by controlled release formulations (see, e.g., US’233 at ¶[0090]). Accordingly, an artisan would readily appreciate that dosing frequency could vary from one to more than one times, as needed. Regarding claims 31, 33-34, and advantages provided before and during surgical steps, Ungaro identifies that refractory ulcerative colitis may require surgical treatment (see, e.g., Ungaro at Fig. 5 at 1763, 1763 at col II at 1st full ¶ identifying that surgery may be required in refractory ulcerative colitis). This is pertinent because the instant claims do not exclude surgical treatment steps (i.e., the claimed method may further “comprise” surgical steps), and US’233 provides guidance that the disclosed compositions (i.e., 0.1-10% (RADA)4) may be advantageously utilized before and during surgery to desirably create “a clean local environment”, “isolate structures and migration of contaminants”, “inflate structures”, etc., etc. (see, e.g., US’233 at ¶[0149]). Accordingly, in addition to the other advantages taught by US’233, an artisan would also readily appreciate that such methods and compositions disclosed by US’233 could be utilized advantageously during surgical correction of refractory ulcerative colitis. Administration would be understood to encompass endoscopic local delivery (see, e.g., US’233 at ¶¶[0173], [0183]). Therefore, it would have been obvious to one of ordinary skill in the art, either before the effective filing date of the claimed invention (AIA ) or otherwise at the time the invention was made (pre-AIA ), to arrive at the instantly claimed invention in view of the prior art for at least the following reason(s): First, the claimed invention is the application of a known method of US’233 for treating any ulcers in gastrointestinal tract by endoscopically administering 0.1-10% (RADA)4 to the refractory ulcers present in refractory ulcerative colitis patients identified by Ungaro, wherein such treatment would predictably and expectedly treat the ulcers in such patients exactly as taught and suggested by US’233 (see, e.g., MPEP § 2143(I)(A), (C), (D), (F), and (G)). Furthermore, each element merely performs its art-recognized function in combination as it does separately. Second, or alternatively, the claimed invention is the application and use of the known surgical method of improving surgeries by using endoscopically administered 0.1-10% (RADA)4 as taught and suggested by US’233, to improve the prior art methodology of treating refractory ulcerative colitis patients by surgical intervention as identified by Ungaro, wherein such combination would yield an improved surgical treatment for refractory ulcerative colitis by utilizing and administering (RADA)4 during and before surgery to obtain the benefits disclosed by US’233 (i.e., to desirably create “a clean local environment”, “isolate structures and migration of contaminants”, “inflate structures”, etc.) (see, e.g., MPEP § 2143(I)(A), (C), (D), (F), and (G)). Accordingly, the claimed invention is rejected as the obvious use and application of known method of improving surgery and treating ulcers using a known compound in a known patient population to obtain known and expected results. No evidence of unexpected results commensurate in scope with the requirements of MPEP §§ 716, 716.01, and 716.02 have been placed on record to date. Furthermore, there would be a reasonable expectation of success because the prior art is presumed fully enabled (see, e.g., MPEP § 2121(I)) for all that it discloses (see, e.g., MPEP §§ 2123(I)-(II)). US’233 is presumed fully enabled for the treatment of all gastrointestinal ulcers, exactly as taught and disclosed by US’233. Accordingly, it is well-within the ordinary skill in the art to utilize a known compound to treat a known condition in a known patient population by performing known steps, wherein the result is taught in the prior art. Accordingly, claims 31 and 33-34 are rejected. Non-Statutory Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 31 and 33-34 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over 31-34 of copending Application No. 19/697,472 (reference application). Although the claims at issue are not identical, they are not patentably distinct from each other because instant claims 31 and 33-34 appear to be directed to substantially identical subject matter as evidenced by the almost identical claim language utilized in copending claims 31 and 33-34 of App’472 as filed 6/20/202610, wherein “containing” at claim 31 of App’472 is reasonably inferred to include the scope of “consisting of” as presently claimed. MPEP § 804(II)(B)(2)-(3) identifies that a Nonstatutory Double Patenting Rejection may be appropriate based upon either an anticipation analysis or an obviousness analysis (see, e.g., MPEP § 804(II)(B)(2)-(3)). Here, it is the Examiner’s position that under an anticipation analysis an artisan would at once envisage the methods recited in the reference claims using the exact, explicitly recited methods presently claimed (see, e.g., MPEP § 804(II)(B)(2)), because the claims are almost, verbatim identical, and the only difference is the usage of “containing” rather than “consisting of” language in App’472. However, an artisan would readily envisage the usage and practice of the copending methods using a peptide “consisting of” instant SEQ ID NO: 1. This is a provisional nonstatutory double patenting rejection because the patentably indistinct claims have not in fact been patented. Accordingly, instant claims 31 and 33-34 are provisionally rejected. Pertinent Prior Art The prior art made of record and not relied upon is considered pertinent to applicant's disclosure. US20240252584 (corresponding to Abandoned US Application 18/264425) pertains to the treatment of ulcers by administering RADA16 (see, e.g., US’584 at title, abs, claims). US20210220429 (corresponding to Abandoned parent Application 17/250,969) pertains to related subject matter. US20230381185 (corresponding to related Application 18/317,002) pertains to methods of treating gastrointestinal diseases by oral administration of a composition (see, e.g., App’002 at claims 13-14 as filed 7/20/2026; see US’185 at claims). US20200078489 (corresponding to Abandoned US Application 16/085,804) pertains to methods of occluding a pancreatic fistula by administering (RADA)4 (see, e.g., US’489 at claims; see App’804 at claims 1-14 as filed 11/19/20219). US 11617778 B2 (corresponding to US Application 16/503039) pertains to a related treatment of ulcers, using a different composition and peptide (see, e.g., US’778 at claims) US 12642836 B2 (corresponding to US Application 18/166956) pertains to a related treatment of ulcers, using a different composition and peptide (see, e.g., US’836 at claims). US 10596255 B2 pertains to a related method of treating bleeding by administering a related but distinct peptide (see, e.g., US’255 at claims). WO2006/116524 Al (Nov. 2, 2006; Ellis-Behnke et al.; cited in 5-page IDS filed 5/29/2024 as Cite No. 3) discloses and teaches the treatment of ulcers using self-assembling peptides, including RADA16 (see, e.g., WO’524 at abs, “Background”, claims). Conclusion No claims are allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to RANDALL L BEANE whose telephone number is (571)270-3457. The examiner can normally be reached Mon.-Fri., 7 AM to 2 PM ET. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Lianko G. Garyu can be reached at (571) 270-7367. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /RANDALL L BEANE/Primary Examiner, Art Unit 1654 1 This corresponds to CAS Registry Number 196400-29-0. 2 Kim, Diagnostic and Treatment Approaches for Refractory Peptic Ulcers. Clin Endosc. 2015 Jul;48(4):285-90. doi: 10.5946/ce.2015.48.4.285. Epub 2015 Jul 24. PMID: 26240800; PMCID: PMC4522418 3 Lee et al., Endoscopic Diagnosis and Differentiation of Inflammatory Bowel Disease. Clin Endosc. 2016 Jul;49(4):370-5. doi: 10.5946/ce.2016.090. Epub 2016 Jul 29. PMID: 27484813; PMCID: PMC4977735. 4See, e.g., Understanding the Structures of the Digestive System, GI Associates & Endoscopy Center (Apr. 11, 2022), also available at https://gi.md/resources/articles/understanding-the-structures-of-the-digestive-system (last visited 12/7/2023); cited in IDS filed 5/29/2024 as Cite No. 7; hereafter “GIAssoc”, at 2, referring to the “intestinal tract” as digesting food and including the oral cavity, esophagus, stomach, pancreas, gallbladder, liver, small intestines, large intestines, colon, appendix, rectum, and anus, at 2-3 referring to “intestinal system” and “gastrointestinal system” synonymously. 5 See, e.g., US 8709784 at col 1 at lines 35-50, referring to microbes surviving the secretions of the “gastrointestinal tract to survive in the digestive system and reach to the intestinal tract to perform its function”, which treat the GI tract and intestinal tract as distinguishable parts of the body. 6 Kim, Diagnostic and Treatment Approaches for Refractory Peptic Ulcers. Clin Endosc. 2015 Jul;48(4):285-90. doi: 10.5946/ce.2015.48.4.285. Epub 2015 Jul 24. PMID: 26240800; PMCID: PMC4522418 7 Ulcerative Colitis: Symptoms, Diagnosis, Risks & Treatment, HexaHealth.com, attached as 13 page pdf (April 22, 2024); also available at https://www.hexahealth.com/condition/ulcerative-colitis (last visited 10/28/2026); hereafter “HexaHealth”. 8 Ungaro et al., Ulcerative colitis, The Lancet, Nov. 30, 2016; vol. 389:1756-1770; hereafter “Ungaro”. 9 The percentages are understood to be given “by weight”, consistent with other portions of US’233 such as ¶¶[0061], [0106]-[0107]. 10 Applicant was informed that this claim set had been entered in App’472 in the Interview of Sept. 24, 2026, mailed 10/01/2026 in the instant Application. However, at the time of the instant action (Oct, 28, 2026), the issue had not been corrected. Examination has proceeded relative to the most recently entered “CLM” document in App’472..
Read full office action

Prosecution Timeline

May 12, 2024
Application Filed
Feb 13, 2025
Response after Non-Final Action
Aug 19, 2026
Response after Non-Final Action
Sep 24, 2026
Applicant Interview (Telephonic)
Sep 29, 2026
Examiner Interview Summary
Oct 30, 2026
Non-Final Rejection mailed — §103, §112, §DOUBLEPATENT (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12773457
IMPLANTABLE DEVICES FOR CELL THERAPY AND RELATED METHODS
5y 7m to grant Granted Oct 27, 2026
Patent 12773443
Insulin Derivative
4y 4m to grant Granted Oct 27, 2026
Patent 12741989
COMPOSITIONS FOR DELIVERY OF ANTISENSE COMPOUNDS
4y 3m to grant Granted Sep 22, 2026
Patent 12734211
USE OF POLYPEPTIDE IN DRUG FOR PREVENTING AND TREATING PNEUMONIA
3y 6m to grant Granted Sep 15, 2026
Patent 12715897
INHIBITORS OF HUMAN EPIDIDYMUS PROTEIN 4
3y 10m to grant Granted Aug 25, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
33%
Grant Probability
69%
With Interview (+36.3%)
3y 3m (~9m remaining)
Median Time to Grant
Low
PTA Risk
Based on 459 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month